J Endocrinol Invest (2018) 41:475–483 https://doi.org/10.1007/s40618-017-0786-8 ORIGINAL ARTICLE Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea: a phase III randomized trial 1 2 3 4 5 6 7 J. Kim · B.‑K. Suh · C. W. Ko · K.‑H. Lee · C. H. Shin · J. S. Hwang · H. S. Kim · 8 9 10 11 1 12 W. Y. Chung · C. J. Kim · H.‑S. Han · N. Y. Kwon · S. Y. Cho · H.‑W. Yoo · D.‑K. Jin Received: 13 July 2017 / Accepted: 25 October 2017 / Published online: 4 November 2017 © The Author(s) 2017. This article is an open access publication Abstract 0.63 ± 0.16 and 0.64 ± 0.46, respectively, for the treatment Purpose Several studies have evaluated the effects of group, and 0.06 ± 0.15 and 0.06 ± 0.28, respectively, for the growth hormone (GH) on auxological and biochemical control group (p < 0.001). Serum insulin-like growth fac- parameters in children with non-GH-deficient, idiopathic tor (IGF-1) and insulin-like growth factor binding protein-3 short stature (ISS). This study evaluated the efficacy and (IGFBP-3) increased significantly in the treatment group at safety of Gr owtropin -II (recombinant human GH) in week 26 compared to baseline. However, the SDS for body Korean patients with ISS. mass index (BMI) at 26 weeks did not change significantly Methods This was a 1-year, open-label, multicenter, phase in either
Journal of Endocrinological Investigation – Springer Journals
Published: Nov 4, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera